Dallas, Texas. December 9, 2022:
Etira is pleased to report the abstract related to ERX-41 validating its activity in Triple negative breast cancer was presented at the San Antonio Breast Cancer Symposium (SABCS). The SABCS is one of the world's…
https://etira.life/wp-content/uploads/2022/12/San-Antonio-Breast-Cancer-Thumbnail-1.jpg661648Ilona Margolishttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngIlona Margolis2022-12-09 15:45:172023-11-30 12:49:50Preclinical data on TNBC presented at SABCS 2022
Dallas, Texas. October 31, 2022. We are pleased to share two news articles from Dallas that describe how our brilliant chemist and founder, Dr. Jung-Mo Ahn discovered ERX-41. In his words, Dr. Ahn describes the discovery of ERX-41 as “It’s…
https://etira.life/wp-content/uploads/2022/10/Annual-Meet-Feature-Image.jpg661648Ilona Margolishttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngIlona Margolis2022-10-31 18:34:572023-11-30 12:50:15Etira founder Dr. Jung-Mo Ahn highlighted in local press
Dallas, Texas. October 10, 2022:etiraRx's lead drug candidate, ERX-41 has been highlighted in the most recent edition of Oncology Times. In an article entitled "Molecule Targets Vulnerability in Triple-Negative Breast Cancer," Dibash Kumar…
https://etira.life/wp-content/uploads/2022/10/Oncology-thumbnail.jpg661648Ilona Margolishttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngIlona Margolis2022-10-10 14:45:172023-11-30 12:55:47Oncology Times Highlights ERX-41
Dallas Texas, September 23, 2022. We are pleased to announce that Etira has been selected as a 2022 BioNTX rising star.
The BioNTX iC³ Life Science Summit is a two-day conference, held on September 22-23, 2022 that serves as a forum where…
https://etira.life/wp-content/uploads/2022/09/bio-ntx.jpg661648Ilona Margolishttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngIlona Margolis2022-09-23 18:41:022023-11-30 12:57:48Etira selected as a 2022 BioNTX rising star
Dallas, Texas. July 7, 2022:
On the cover of the July 2022 issue of Nature cancer is an image of the endoplasmic reticulum within a cell. Image courtesy of Dr. Andrew S. Moore, Janelia Research Campus. Cover Design by Allen Beattie. Highlighted…
https://etira.life/wp-content/uploads/2023/06/nature-cancer-cover-1.jpg743556Ilona Margolishttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngIlona Margolis2022-07-10 15:30:512023-11-30 12:57:25ERX-41 Paper image selected for Nature Cancer cover
https://etira.life/wp-content/uploads/2022/07/Scientific-Thumbnail.jpg661648Ilona Margolishttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngIlona Margolis2022-07-01 09:23:172023-11-30 13:02:24Scientific News Media Features the Discovery of ERX-41, the Novel Mechanism of Action and Novel Molecular Target
Patients must be at least 18 years of age at the time of signing the informed consent.
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
Patients must have histologically or cytologically confirmed solid tumor, primarily including but not limited to breast, ovarian, pancreatic, endometrial, and hepatocellular carcinoma, that is advanced unresectable and/or metastatic disease for whom standard therapies do not exist or are no longer effective
Patients must have measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
Adequate baseline organ function and hematologic function
Life expectancy >3 months
Exclusion criteria
Systemic anti-cancer therapy within 4 weeks of first dose of study drug
Major surgery (as defined by the Investigator) within 4 weeks of first dose of study drug.
Uncontrolled intercurrent illnesses
Known history of LIPA deficiency, such as Wolman disease or Cholesterol ester storage disease.
Preclinical data on TNBC presented at SABCS 2022
NewsEtira founder Dr. Jung-Mo Ahn highlighted in local press
NewsOncology Times Highlights ERX-41
NewsEtira selected as a 2022 BioNTX rising star
NewsERX-41 Paper image selected for Nature Cancer cover
NewsScientific News Media Features the Discovery of ERX-41, the Novel Mechanism of Action and Novel Molecular Target
News